<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cinnarizine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00568</strong>&#160; (APRD00332)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Cinnarizine is an anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955.</p>
<p>It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception.</p>
<p>Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00568/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00568/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00568.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00568.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00568.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00568.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00568.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00568">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>1-Benzhydryl-4-cinnamylpiperazin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>1-Cinnamyl-4-(diphenylmethyl)piperazine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cinarizina</td><td>Spanish</td><td>INN</td></tr><tr><td>Cinnarizin</td><td>German</td><td>INN</td></tr><tr><td>Cinnarizine</td><td>French</td><td>INN</td></tr><tr><td>Cinnarizinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cinazyn</td><td>Italchimici</td></tr><tr><td>Cinnageron</td><td>Streuli Pharma</td></tr><tr><td>Folcodal</td><td>Ivax</td></tr><tr><td>Sepan</td><td>Janssen-Cilag</td></tr><tr><td>Stugeron</td><td>Janssen</td></tr><tr><td>Stugeron Forte</td><td>Janssen</td></tr><tr><td>Toliman</td><td>Scharper</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Arlevert</td><td>Cinnarizine and Dimenhydrinate</td></tr><tr><td>Arlevertan</td><td>Cinnarizine and Dimenhydrinate</td></tr><tr><td>Azinorm-C</td><td>Cinnarizine and Domperidone</td></tr><tr><td>Cinacris forte</td><td>Cinnarizine and Dihydroergocristine</td></tr><tr><td>Cinageron</td><td>Cinnarizine and Dihydroergocristine</td></tr><tr><td>Clinadil</td><td>Cinnarizine and Dihydroergocristine</td></tr><tr><td>Combitropil</td><td>Cinnarizine and Piracetam</td></tr><tr><td>Domstal-CZ</td><td>Cinnarizine and Domperidone</td></tr><tr><td>Exit</td><td>Cinnarizine and Piracetam</td></tr><tr><td>Fesamol</td><td>Cinnarizine and Piracetam</td></tr><tr><td>Omaron</td><td>Cinnarizine and Piracetam</td></tr><tr><td>Phezam</td><td>Cinnarizine and Piracetam</td></tr><tr><td>Primatour</td><td>Cinnarizine and Chlorcyclizine</td></tr><tr><td>Rinomar</td><td>Cinnarizine and Phenylpropanolamine</td></tr><tr><td>Touristil</td><td>Cinnarizine and Domperidone</td></tr><tr><td>Vernavo</td><td>Cinnarizine and Domperidone</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>298-57-7</td></tr><tr><th>Weight</th><td>Average: 368.5139<br>Monoisotopic: 368.225248906</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>28</sub>N<sub>2</sub></td></tr><tr><th>InChI Key</th><td>DERZBLKQOCDDDZ-JLHYYAGUSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-(diphenylmethyl)-4-(3-phenylprop-2-en-1-yl)piperazine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Diphenylmethanes</td></tr><tr><th>Direct parent</th><td>Diphenylmethanes</td></tr><tr><th>Alternative parents</th><td>Phenylpropenes; Styrenes; Diazinanes; Piperazines; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>phenylpropene; styrene; 1,4-diazinane; piperazine; tertiary amine; polyamine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.</td></tr><tr><th>Pharmacodynamics</th><td>Cinnarizine is an antihistamine and a calcium channel blocker. Histamines mediate a number of activities such as contraction of smooth muscle of the airways and gastrointestinal tract, vasodilatation, cardiac stimulation, secretion of gastric acid, promotion of interleukin release and chemotaxis of eosinophils and mast cells. Competitive antagonists at histamine H1 receptors may be divided into first (sedating) and second (non-sedating) generation agents. Some, such as Cinnarizine also block muscarinic acetylcholine receptors and are used as anti-emetic agents. Cinnarizine through its calcium channel blocking ability also inhibits stimulation of the vestibular system.</td></tr><tr><th>Mechanism of action</th><td>Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking L-type and T-type voltage gated calcium channels. Cinnarizine has also been implicated in binding to dopamine D2 receptors, histamine H1 receptors, and muscarinic acetylcholine receptors. </td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Cinnarizine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li></ul></td><td><a href="/metabolites/DBMET01193">Cinnarizine metabolite M1</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1337">Details</a></td></tr><tr><td>Cinnarizine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET01194">Cinnarizine metabolite M2</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1338">Details</a></td></tr><tr><td>Cinnarizine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003336" target="_blank">Cytochrome P450 2A6</a></li></ul></td><td><a href="/metabolites/DBMET01195">Benzophenone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1339">Details</a></td></tr><tr><td>Cinnarizine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET01196">Cinnarizine metabolite M4</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1340">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9506</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.977</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6409</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7107</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7461</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8398</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7902</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8549</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7558</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.7732</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9488</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9346</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9279
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9496
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9968
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0618 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5724
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.524
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>